Sequential Bioactivation of Methoxime Analogs of β-Adrenergic Antagonists in the Eye

Nicholas Bodor, Laszlo Prokai, Whei Mei Wu, Gabor Somogyi, Hassan Farag

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Selected β-adrenoreceptor antagonists are the antiglaucoma drugs of first choice in most cases. However, a number of significant central nervous system (CNS), cardiovascular and respiratory side-effects following topical ocular installation of β-blockers have also been reported. Site- and stereo-specific delivery to the eye of β-blockers was achieved by application of a sequential bioactivation of the chemical delivery system (CDS) analogs of these drugs, which are converted to the active β-blockers only in the eye, thus systemic side effects are avoided. The corresponding ketoxime analogs of the various β-blockers were successfully applied and one of them, Alprenoxime, was tested in humans. The main problem with these compounds, however, is formulation stability: Alprenoxime has a t90 of only 2-3 months. Thus, alternate structures were searched. Methoxime analogs of selected β-blockers were synthesized and their chemical stability established at different pH's. Subsequently, their in vivo sequential enzymatic conversion was confirmed using HPLC. Comparative intraocular pressure (IOP) reducing activity of the methoximes were then studied using normotensive rabbits. The methoxime analogs showed significantly improved hydrolytic stability at pH ∼ 7.0, the t90 is over 1 year. The in vivo sequential bioactivation, however, proceeds similarly to the oximes. The intermediate ketones and the active β-blockers can be detected in the various eye compartments at different time intervals following topical administration of the methoximes. The mechanism of the eye-selective bioactivation and the results of the IOP reducing activity studies will be discussed.

Original languageEnglish
Pages (from-to)305-318
Number of pages14
JournalJournal of Ocular Pharmacology and Therapeutics
Volume11
Issue number3
DOIs
StatePublished - 1 Jan 1995

Fingerprint

Adrenergic Antagonists
Oximes
Intraocular Pressure
Topical Administration
Drug Delivery Systems
Ketones
Central Nervous System
High Pressure Liquid Chromatography
N,N'-monomethylenebis(pyridiniumaldoxime)
Rabbits
Pharmaceutical Preparations

Cite this

Bodor, Nicholas ; Prokai, Laszlo ; Wu, Whei Mei ; Somogyi, Gabor ; Farag, Hassan. / Sequential Bioactivation of Methoxime Analogs of β-Adrenergic Antagonists in the Eye. In: Journal of Ocular Pharmacology and Therapeutics. 1995 ; Vol. 11, No. 3. pp. 305-318.
@article{f04f0720612b449b850072db317e6c9a,
title = "Sequential Bioactivation of Methoxime Analogs of β-Adrenergic Antagonists in the Eye",
abstract = "Selected β-adrenoreceptor antagonists are the antiglaucoma drugs of first choice in most cases. However, a number of significant central nervous system (CNS), cardiovascular and respiratory side-effects following topical ocular installation of β-blockers have also been reported. Site- and stereo-specific delivery to the eye of β-blockers was achieved by application of a sequential bioactivation of the chemical delivery system (CDS) analogs of these drugs, which are converted to the active β-blockers only in the eye, thus systemic side effects are avoided. The corresponding ketoxime analogs of the various β-blockers were successfully applied and one of them, Alprenoxime, was tested in humans. The main problem with these compounds, however, is formulation stability: Alprenoxime has a t90 of only 2-3 months. Thus, alternate structures were searched. Methoxime analogs of selected β-blockers were synthesized and their chemical stability established at different pH's. Subsequently, their in vivo sequential enzymatic conversion was confirmed using HPLC. Comparative intraocular pressure (IOP) reducing activity of the methoximes were then studied using normotensive rabbits. The methoxime analogs showed significantly improved hydrolytic stability at pH ∼ 7.0, the t90 is over 1 year. The in vivo sequential bioactivation, however, proceeds similarly to the oximes. The intermediate ketones and the active β-blockers can be detected in the various eye compartments at different time intervals following topical administration of the methoximes. The mechanism of the eye-selective bioactivation and the results of the IOP reducing activity studies will be discussed.",
author = "Nicholas Bodor and Laszlo Prokai and Wu, {Whei Mei} and Gabor Somogyi and Hassan Farag",
year = "1995",
month = "1",
day = "1",
doi = "10.1089/jop.1995.11.305",
language = "English",
volume = "11",
pages = "305--318",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

Sequential Bioactivation of Methoxime Analogs of β-Adrenergic Antagonists in the Eye. / Bodor, Nicholas; Prokai, Laszlo; Wu, Whei Mei; Somogyi, Gabor; Farag, Hassan.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 11, No. 3, 01.01.1995, p. 305-318.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sequential Bioactivation of Methoxime Analogs of β-Adrenergic Antagonists in the Eye

AU - Bodor, Nicholas

AU - Prokai, Laszlo

AU - Wu, Whei Mei

AU - Somogyi, Gabor

AU - Farag, Hassan

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Selected β-adrenoreceptor antagonists are the antiglaucoma drugs of first choice in most cases. However, a number of significant central nervous system (CNS), cardiovascular and respiratory side-effects following topical ocular installation of β-blockers have also been reported. Site- and stereo-specific delivery to the eye of β-blockers was achieved by application of a sequential bioactivation of the chemical delivery system (CDS) analogs of these drugs, which are converted to the active β-blockers only in the eye, thus systemic side effects are avoided. The corresponding ketoxime analogs of the various β-blockers were successfully applied and one of them, Alprenoxime, was tested in humans. The main problem with these compounds, however, is formulation stability: Alprenoxime has a t90 of only 2-3 months. Thus, alternate structures were searched. Methoxime analogs of selected β-blockers were synthesized and their chemical stability established at different pH's. Subsequently, their in vivo sequential enzymatic conversion was confirmed using HPLC. Comparative intraocular pressure (IOP) reducing activity of the methoximes were then studied using normotensive rabbits. The methoxime analogs showed significantly improved hydrolytic stability at pH ∼ 7.0, the t90 is over 1 year. The in vivo sequential bioactivation, however, proceeds similarly to the oximes. The intermediate ketones and the active β-blockers can be detected in the various eye compartments at different time intervals following topical administration of the methoximes. The mechanism of the eye-selective bioactivation and the results of the IOP reducing activity studies will be discussed.

AB - Selected β-adrenoreceptor antagonists are the antiglaucoma drugs of first choice in most cases. However, a number of significant central nervous system (CNS), cardiovascular and respiratory side-effects following topical ocular installation of β-blockers have also been reported. Site- and stereo-specific delivery to the eye of β-blockers was achieved by application of a sequential bioactivation of the chemical delivery system (CDS) analogs of these drugs, which are converted to the active β-blockers only in the eye, thus systemic side effects are avoided. The corresponding ketoxime analogs of the various β-blockers were successfully applied and one of them, Alprenoxime, was tested in humans. The main problem with these compounds, however, is formulation stability: Alprenoxime has a t90 of only 2-3 months. Thus, alternate structures were searched. Methoxime analogs of selected β-blockers were synthesized and their chemical stability established at different pH's. Subsequently, their in vivo sequential enzymatic conversion was confirmed using HPLC. Comparative intraocular pressure (IOP) reducing activity of the methoximes were then studied using normotensive rabbits. The methoxime analogs showed significantly improved hydrolytic stability at pH ∼ 7.0, the t90 is over 1 year. The in vivo sequential bioactivation, however, proceeds similarly to the oximes. The intermediate ketones and the active β-blockers can be detected in the various eye compartments at different time intervals following topical administration of the methoximes. The mechanism of the eye-selective bioactivation and the results of the IOP reducing activity studies will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0029130880&partnerID=8YFLogxK

U2 - 10.1089/jop.1995.11.305

DO - 10.1089/jop.1995.11.305

M3 - Article

C2 - 8590263

AN - SCOPUS:0029130880

VL - 11

SP - 305

EP - 318

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -